<abstract><sec><title>Background</title><p>Duloxetine, Etoricoxib and opioid are of the commonly administered
    drugs in Lumbar laminectomy. The aim of this study is to assess the effect
    of perioperative use of Duloxetine in combination with Etoricoxib on
    postoperative pain and opioid requirements.</p></sec><sec><title>Methods</title><p>One hundred twenty patients with ASA physical status were enrolled
    with age between 18 and 70 years. Patients were divided randomly
    into four groups of 30 patients: group P received placebo, group E received
    etoricoxib 120 mg, group D received duloxetine 60 mg and
    group D/E received duloxetine 60 mg capsules and etoricoxib
    120 mg; 1 h before surgery and 24 h after.</p></sec><sec><title>Results</title><p>Neither Duloxetine nor etoricoxib individually had effect on pain
    with movement, while their combination revealed a significant reduction in
    pain scores over the entire postoperative period at rest and on movement.
    Etoricoxib showed a significant decrease in pain at all times at rest when
    compared with group P, while it showed significant pain decrease only at 0,
    2 and 4 h when compared with group D. On the other hand duloxetine
    alone showed significant decrease in pain at rest at 24 h and
    48 h when compared with group P. ConcerningMorphine requirement
    after 24 h.; it wassignificantly lower in the D/E group in
    comparison with groups P, E and D. It should be noted also that there was a
    significant decrease morphine requirement in both groups E and D.</p></sec><sec><title>Conclusion</title><p>The perioperative administration of the combination of etoricoxib
    and duloxetine improved analgesia and reduced opioid consumption without
    significant side effects.</p></sec><sec><title>Trial registration</title><p><ext-link>
    ISRCTN48329522</ext-link>. 17 June 2017</p></sec></abstract><sec><title>Results</title><p>From November 1, 2015 to March 1, 2017, 131 consecutive patients who met the
inclusion criteria were allocated for the study (Fig. <xref>1</xref>). Eleven patients refused to participate. Therefore, 120
patients were randomized and included in the study. Characteristics of patients and surgical
procedures for each group (Table <xref>
    1</xref>) showed no significant differences between the groups.<fig><label>Fig. 1</label><caption><p>Flow diagram for participant</p></caption><graphic></graphic></fig><table-wrap><label>Table 1</label><caption><p>Characteristics of patients and surgical procedures in the four groups</p></caption><table><thead><tr><th>Group<break></break>Variable</th><th>Group (P)<break></break>(<italic>n</italic> = 30)</th><th>Group (E)<break></break>(<italic>n</italic> = 30)</th><th>Group (D)<break></break>(<italic>n</italic> = 30)</th><th>Group (D/E)<break></break>(<italic>n</italic> = 30)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Age (years)</td><td>46.50 ± 8.74</td><td>45.26 ± 7.50</td><td>48.36 ± 9.80</td><td>47.50 ± 10.14</td><td>0.455</td></tr><tr><td>Male/Female (n)</td><td>15/15</td><td>17/13</td><td>18/12</td><td>16/14</td><td>0.471</td></tr><tr><td>Weight (kg)</td><td>81.23 ± 13.24</td><td>82.53 ± 12.90</td><td>80.60 ± 13.37</td><td>78.83 ± 16.78</td><td>0.794</td></tr><tr><td>Height (cm)</td><td>167.46 ± 8.50</td><td>165.53 ± 7.71</td><td>165.40 ± 8.21</td><td>165.00 ± 9.63</td><td>0.478</td></tr><tr><td>ASA (n)</td></tr><tr><td> I</td><td>18</td><td>18</td><td>17</td><td>15</td><td>0.36</td></tr><tr><td> II</td><td>7</td><td>6</td><td>9</td><td>10</td><td>0.42</td></tr><tr><td> III</td><td>5</td><td>6</td><td>4</td><td>5</td><td>0.23</td></tr><tr><td> Duration of surgery (min)</td><td>109.9 ± 10.8</td><td>115.7 ± 9.8</td><td>113.2 ± 13.7</td><td>117.8 ± 9.7</td><td>0.65</td></tr></tbody></table><table-wrap-foot><p>Data are presented as Mean ± SD or number (n)</p><p>Placebo group (P), Etoricoxib group (E), Duloxetine group (D),
Duloxetine/Etoricoxib group (D/E). Data were analyzed using ANOVA test with post hoc
            test (Bonferroni) and chi square test</p></table-wrap-foot></table-wrap></p><sec><title>The morphine requirement</title><p>The time to first rescue analgesic was significantly prolonged in (D/E)when
    compared with group D, group E and group P.There was a significant prolongation when
    groups E and D were compared with group P respectively with no significant difference
    between group E and group D (Fig. <xref>2</xref>).<fig><label>Fig. 2</label><caption><p>Time to morphine administration after surgery in the four groups as
                Mean(SD). Placebo group (P), etoricoxib (E), Duloxetine (D),
    Duloxetine/etoricoxib (D/E). a: when compared with P group. b: when compared
                with E group. c: when compared with D group. d: when compared with E/D group</p></caption><graphic></graphic></fig></p><p>The morphine requirement at 24 h was statistically different
    between the four groups.</p><p>. There were significantly increased morphine requirements in the P group
    compared with E, D and D/E groups and significantly increased in E and D groups
    respectively when compared with D/E group with no significant difference between group E
    and group D (Fig. <xref>3</xref>). At 48 h,
    total morphine requirement were still significantly increased in the P group compared
    with all groups with significant increases in both E and D groups when compared with D/E
    group with no significant difference between group E and group D (Fig. <xref>4</xref>). But it was still significantly lower in the
    three groups at 48 h post-surgery when compared with those required at24 h.<fig><label>Fig. 3</label><caption><p>Morphine requirements at 24 h in the four groups as mean
                (SD). Placebo group (P), etoricoxib (E), Duloxetine (D),
    Duloxetine/etoricoxib
                (D/E). a: when compared with P group. b: when compared with E group. c: when
    compared with D group. d: when compared with E/D group</p></caption><graphic></graphic></fig><fig><label>Fig. 4</label><caption><p>Morphine requirements at 48 h in the four groups as mean
                (SD). Placebo group (P), etoricoxib (E), Duloxetine (D),
    Duloxetine/etoricoxib
                (D/E). a: when compared with P group. b: when compared with E group. c: when
    compared with D group. d: when compared with E/D group</p></caption><graphic></graphic></fig></p></sec><sec><title>The pain score</title><p>With regard to pain scores at rest all time points, the duloxetine/etoricoxib
    (D/E) group had significantly lower pain scores when compared to placebo group P, while
    when it compared to etoricoxib group E, also when compared D/E with duloxetine group D
    (Table <xref>2</xref>).<table-wrap><label>Table 2</label><caption><p>Pain scores (NRS) at rest in the four groups</p></caption><table><thead><tr><th>Group<break></break>Variable</th><th>Group (P)<break></break>(<italic>n</italic> = 30)</th><th>Group (E)<break></break>(<italic>n</italic> = 30)</th><th>Group (D)<break></break>(<italic>n</italic> = 30)</th><th>Group (D/E)<break></break>(<italic>n</italic>  = 30)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>At 0 h</td><td>5 (4-5.25)<sup>bd</sup></td><td>4 (3-4) <sup>acd</sup></td><td>4 (3-5) <sup>bd</sup></td><td>3 (3-4) <sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 2 h</td><td>4 (3-5)bd</td><td>3 (3-4) <sup>acd</sup></td><td>4 (3-5) <sup>bd</sup></td><td>3 (3-3)<sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 4 h</td><td>4 (3-5) <sup>bd</sup></td><td>3 (3-4) <sup>acd</sup></td><td>3 (3-4) <sup>bd</sup></td><td>2 (2-3)<sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 6 h</td><td>3 (3-4) <sup>bd</sup></td><td>3 (2-4) <sup>ad</sup></td><td>2.5 (2-3)<sup>d</sup></td><td>2 (1-3) <sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 12 h</td><td>3 (3-3) <sup>bd</sup></td><td>3 (2-3) <sup>ad</sup></td><td>3 (2-3)<sup>d</sup></td><td>2.5 (1-3) <sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 24 h</td><td>3 (2-3) <sup>bcd</sup></td><td>2(2-3) <sup>ad</sup></td><td>2.5 (2-3) <sup>ad</sup></td><td>2 (1-2)<sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 48 h</td><td>3 (2-3) <sup>bcd</sup></td><td>2 (2-3) <sup>ad</sup></td><td>2 (2-3) <sup>ad</sup></td><td>2 (0.75-2)<sup>abc</sup></td><td>0.0001</td></tr></tbody></table><table-wrap-foot><p>Placebo group (P), Etoricoxib (E), Duloxetine (D),
                Duloxetine/Etoricoxib (D/E)</p><p>Data are presented as median (interquartile range). Data were analyzed by
    Mann–Whitney U-test and kruksal-wallis test and <italic>P</italic> &lt; 0.05
    is considered significant</p><p>a: when compared with P group</p><p>b: when compared with E group</p><p>c: when compared with D group</p><p>d: when compared with D/E group</p></table-wrap-foot></table-wrap></p><p>The pain score in group E was significantly decreased at most time periods
    when compared to group P at 0, 2 and 4 h at rest when compared with group D. The
    pain score in group D was significantly decrease at 24 and 48 h compared to
    group P (Table <xref>2</xref> ).</p><p>While on movement pain was significantly decreased in D/E at all times when
    compared togroup P and when it compared to group E and when it compared to group D with
    no significant difference between other groups on movement (Table <xref>3</xref>).<table-wrap><label>Table 3</label><caption><p>Pain scores (NRS) on movement in the four groups</p></caption><table><thead><tr><th>Group<break></break>Variable</th><th>Group (P)<break></break>(<italic>n</italic> = 30)</th><th>Group (E)<break></break>(<italic>n</italic> = 30)</th><th>Group (D)<break></break>(<italic>n</italic> = 30)</th><th>Group (D/E)<break></break>(<italic>n</italic>  = 30)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>0 h</td><td>5 (5-6.25) <sup>d</sup></td><td>5 (5-6) <sup>d</sup></td><td>5 (5-6) <sup>d</sup></td><td>5 (4.5.25) <sup>abc</sup></td><td>0.013</td></tr><tr><td>After 2 h</td><td>5 (5-6) <sup>d</sup></td><td>5 (4-6) <sup>d</sup></td><td>5 (5-6) <sup>d</sup></td><td>5 (4-5) <sup>abc</sup></td><td>0.002</td></tr><tr><td>After 4 h</td><td>4 (4-5) <sup>d</sup></td><td>4 (4-5) <sup>d</sup></td><td>4 (4-5) <sup>d</sup></td><td>4 (3-4) <sup>abc</sup></td><td>0.019</td></tr><tr><td>After 6 h</td><td>4 (3-5) <sup>d</sup></td><td>4 (3-5) <sup>d</sup></td><td>4 (4-5) <sup>d</sup></td><td>4 (3-4) <sup>abc</sup></td><td>0.007</td></tr><tr><td>After 12 h</td><td>4 (3-5) <sup>d</sup></td><td>4 (3-4) <sup>d</sup></td><td>4 (3-4.25) <sup>d</sup></td><td>3 (3-4) <sup>abc</sup></td><td>0.030</td></tr><tr><td>After 24 h</td><td>4 (3-5) <sup>d</sup></td><td>4 (3-4.25) <sup>d</sup></td><td>4 (3-4) <sup>d</sup></td><td>3 (2.75-4) <sup>abc</sup></td><td>0.059</td></tr><tr><td>After 48 h</td><td>3.5 (3-4) <sup>d</sup></td><td>3 (3-4) <sup>d</sup></td><td>3.5 (3-4) <sup>d</sup></td><td>3 (2.75-4) <sup>abc</sup></td><td>0.049</td></tr></tbody></table><table-wrap-foot><p>Placebo group (P), Etoricoxib (E), Duloxetine (D),
                Duloxetine/Etoricoxib (D/E)</p><p>Data are presented as median (interquartile range). Data were analyzed by
    Mann–Whitney U-test and kruksal-wallis test and <italic>P</italic> &lt; 0.05
    is considered significant. a: when compared with P group</p><p>b: when compared with E group</p><p>c: when compared with D group</p><p>d: when compared with D/E group</p></table-wrap-foot></table-wrap></p></sec><sec><title>Patients’ satisfaction</title><p>The percentage of patients’ satisfaction (excellent) shows significant
    differences between the four groups at 24 h (Table <xref>4</xref>) with no significant differences between the
    three groups at 48 h.<table-wrap><label>Table 4</label><caption><p>Patient’s satisfaction in the four groups at 24 h</p></caption><table><thead><tr><th>Group<break></break>Patient satisfaction</th><th>Group(P)<break></break>(<italic>n</italic> = 30)</th><th>Group(E)<break></break>(<italic>n</italic> = 30)</th><th>Group(D)<break></break>(<italic>n</italic> = 30)</th><th>Group(D/E)<break></break>(<italic>n</italic> = 30)</th><th>p</th></tr></thead><tbody><tr><td>ExEellent</td><td>9 (30%)</td><td>12(40%)</td><td>11(36.7%)</td><td>21 (63.3%)*</td><td>0.004</td></tr><tr><td>Good</td><td>9(30%)</td><td>10(33.3%)</td><td>9(30%)</td><td>5(23.3%)</td><td>0.237</td></tr><tr><td>Fair</td><td>8(26.7%)</td><td>5 (16.5%)</td><td>6(20%)</td><td>2(6.7%)</td><td>0.069</td></tr><tr><td>Poor</td><td>4(13.3%)</td><td>3(10%)</td><td>3(10%)</td><td>2(6.7%)</td><td>0.933</td></tr></tbody></table><table-wrap-foot><p>Data are presented as number (%). Data were analyzed using chi square.
    Placebo group (P), Etoricoxib (E), Duloxetine (D), Duloxetine/Etoricoxib (D/E). <italic>
    P</italic> &lt; 0.05 is considered significant</p><p>*<italic>P</italic> = 0.016 when compare with P</p></table-wrap-foot></table-wrap></p><p>The most common adverse effect expected by patients in the study was nausea
    and vomiting grades III and IV. There was a significant increase in percentage of
    patients in group P (43.3%) when compared with group D/E (16.6%) and who reported nausea
    and vomiting. All complained patients responded to i.v.ondansetron. No statistically
    significant differences were noted between groups with regard to adverse effects
    (Table <xref>5</xref>).<table-wrap><label>Table 5</label><caption><p>Side effects in the four groups</p></caption><table><thead><tr><th>Group<break></break>Side effect</th><th>Group(P)<break></break>(<italic>n</italic> = 30)</th><th>Group(E)<break></break>(<italic>n</italic> = 30)</th><th>Group(D)<break></break>(<italic>n</italic> = 30)</th><th>Group(D/E)<break></break>(<italic>n</italic> = 30)</th><th>p</th></tr></thead><tbody><tr><td>PONV (%)<break></break>IIII&amp;IV</td><td>13 (43.3%)*</td><td>7 (23.3%)</td><td>7 (23.3%)</td><td>5 (16.6%)</td><td>0.027</td></tr><tr><td>Somnolence</td><td>1 (3.3%)</td><td>1 (3.3%)</td><td>2 (6.7%)</td><td>3 (10%)</td><td>0.225</td></tr><tr><td>Pruritus</td><td>5 (16.7%)</td><td>4 (13.3%)</td><td>3 (10%)</td><td>3 (10%)</td><td>0.390</td></tr><tr><td>Dizziness</td><td>1 (3.3%)</td><td>2 (6.7%)</td><td>4 (13.3%)</td><td>3 (10%)</td><td>0.239</td></tr><tr><td>Headache</td><td>6 (20%)</td><td>3 (10%)</td><td>5 (16.7%)</td><td>4 (13.3%)</td><td>0.907</td></tr></tbody></table><table-wrap-foot><p>Data are presented as number (%). Data were analyzed using chi square test
    and fisher’s exact test. Placebo group (P), Etoricoxib (E), Duloxetine (D),
    Duloxetine/Etoricoxib (D/E). <italic>P</italic> &lt; 0.05 is
    considered significant. *<italic>P</italic> = 0.024 when compare P and
    D/E</p></table-wrap-foot></table-wrap></p></sec></sec>